BIO Submits Comments Re: MIPS, Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models RFI
<p>Andy Slavitt</p>
<p>Acting Administrator</p>
<p>Centers for Medicare and Medicaid Services</p>
<p>7500 Security Boulevard</p>
<p>Baltimore, M.D. 22224</p>
<p><strong><em>BY ELECTRONIC DELIVERY</em></strong></p>
<p><strong>RE: CMS Regarding Implementation of the Merit-Based Incentive Payment System, Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models</strong></p>
<p>Dear Acting Administrator Slavitt:</p>
<p>The Biotechnology Industry Organization is pleased to submit feedback in response to the Centers for Medicare and Medicaid Services’ (CMS’s) Request for Information entitled “CMS Regarding Implementation of the Merit-Based Incentive Payment System (MIPS), Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models,” (the “RFI”) released October 1, 2015.</p>
Andy Slavitt
Acting Administrator
Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, M.D. 22224
BY ELECTRONIC DELIVERY
RE: CMS Regarding Implementation of the Merit-Based Incentive Payment System, Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models
Dear Acting Administrator Slavitt:
The Biotechnology Industry Organization is pleased to submit feedback in response to the Centers for Medicare and Medicaid Services’ (CMS’s) Request for Information entitled “CMS Regarding Implementation of the Merit-Based Incentive Payment System (MIPS), Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models,” (the “RFI”) released October 1, 2015.
BIO advocates on behalf of biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.
